Article By:
Tarun Chandra, CFA
Sunday, December 17, 2017 11:58 AM EDT
Biotech is not an easy sector to invest in - 95 percent of the oncology drugs that enter clinical trials fail. But that is no reason to ignore biotechs. We believe biotech stocks in 2018 will deliver double-digit returns of around 20%.
In this article: ALNY, ALXN, ABEO Also: ASH, ARNA, AMGN, BIIB, ANAB, SPPI, ZGNX, NKTR, EXAS, SAGE, HALO, SGMO, DVAX, INSM, XBI, JUNO, ESPR, LOXO, RVNC, LABD, LABU, BPMC, MRTX, NVS, CLLS, BLUE, BMY, INCY, CELG, GILD, VRTX, REGN
Intercept Downgraded To Sell From Neutral At H.C. Wainwright
Does this matter? They upgraded one of my stocks last week $ABEO to a price that is 3 times the price then and it went down so hard since then. Screw the Anal-ysts.